Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals PLC has filed a post-effective amendment to its Form F-1 to update a resale registration covering 109,800,000 Ordinary Shares, represented by 1,098 American Depositary Shares, issuable upon exercise of June 2023 Series D warrants. These shares may be sold from time to time by the selling shareholders, and all resale proceeds will go to those shareholders, not the company. Biodexa may receive up to approximately $4.4 million only if all Series D warrants are exercised for cash. The company remains a clinical-stage biopharma focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, while MTX110 for rare brain cancers has been de-prioritized. As of September 30, 2025, Biodexa reported £2.79 million in cash and cash equivalents and continues to rely on warrant exercises, equity facilities and grants to fund its programs.
Biodexa Pharmaceuticals PLC filed Prospectus Supplement No. 10 to its Form F-1, covering the resale by selling shareholders of up to 4,349,000,000 ordinary shares represented by 43,490 American Depositary Shares.
The supplement incorporates a Form 6-K announcing EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), permitting the study to proceed in Europe across sites in Denmark, Germany, the Netherlands and Spain, with Italy expected to be added. The company noted the first European patient is expected in 4Q 2025, and the U.S. arm enrolled its first patient in mid-August 2025. The registrational study plans to recruit 168 patients, randomized 2:1 (drug:placebo). Biodexa cited an addressable US–European market of $7 billion. The company’s ADS trade on Nasdaq as BDRX; the last reported close was $6.49 on October 31, 2025.
Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale of up to 341,352,000,000 ordinary shares represented by 3,413,520 American Depositary Shares under its effective F-1. The Depositary Shares trade on NASDAQ as BDRX; the last reported closing price was $6.49 on October 31, 2025.
The supplement also incorporates a Form 6-K announcing EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis, allowing the study to proceed in Europe at sites in Denmark, Germany, the Netherlands, and Spain, with Italy expected to be added. The U.S. arm enrolled its first patient in mid‑August 2025, and the company expects the first European patient in 4Q 2025. The Phase 3 study is randomized, double‑blind, and placebo‑controlled, with a planned enrollment of 168 patients randomized 2:1 drug to placebo.
Biodexa Pharmaceuticals PLC filed a prospectus supplement to its Form F-1 resale registration and incorporated a new Form 6-K. The update highlights European regulatory progress for its lead program.
The company announced EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. The CTA permits sites in Denmark, Germany, the Netherlands, and Spain, with Italy expected to be added. The U.S. arm enrolled its first patient in mid-August 2025, and the first European patient is expected in 4Q 2025. The Serenta study is a randomized, double-blind, placebo-controlled registrational trial targeting 168 patients, randomized 2:1 to drug versus placebo. Management cited a $7 billion combined U.S.–Europe addressable market for FAP.
Biodexa’s ADS trade on Nasdaq under BDRX; the last reported closing price on October 31, 2025 was $6.49.
Biodexa Pharmaceuticals (BDRX) reported EMA approval of its Clinical Trial Application, allowing its pivotal Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (FAP) to proceed in Europe.
The CTA covers trial sites in Denmark, Germany, the Netherlands and Spain, with Italy expected to be added. The company also furnished a press release as Exhibit 99.1.
The information under this CTA approval heading is incorporated by reference into the company’s registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-290554), as stated.
Biodexa Pharmaceuticals announced on August 18, 2025 that the first two patients were enrolled in its pivotal Phase 3 Serenta trial of eRapa for familial adenomatous polyposis (FAP) by the Pan American Center for Oncology Trials in San Juan, Puerto Rico. The notice states this enrollment information is incorporated by reference into the company's Form S-8 and Form F-3 registration statements. The company also furnished a press release dated August 18, 2025 as Exhibit 99.1 to the Form 6-K; that exhibit is being furnished and not filed for Exchange Act liability purposes.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has filed a Prospectus Supplement No. 5 to incorporate information from their Form 6-K dated June 27, 2025. The filing covers the resale of 2,486,190,000 ordinary shares (representing 248,619 American Depositary Shares) by selling shareholders.
Key highlights:
- All resolutions at the Annual General Meeting held on June 26, 2025, were successfully passed
- Last reported closing price of ADSs was $0.9215 on NASDAQ Capital Market
- Company's pipeline includes three main development programs: - eRapa: For Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer - Tolimidone: For type 1 diabetes treatment - MTX110: For aggressive rare/orphan brain cancer indications
The company leverages three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of medicines, with headquarters and R&D facility in Cardiff, UK.